Level D· Scientific groundwork from lab and animal studiesAnimal StudyPubMed

Improvement of cardiac function and remodeling by transplanting adipose tissue-derived stromal cells into a mouse model of acute myocardial infarction.

Yu LH., Kim MH., Park TH., Cha KS., Kim YD., Quan ML.

Animal Study with a reported sample of 15 on Cardiovascular Disease, Scar, published in Int J Cardiol (2008) — summary generated from the PubMed abstract.

Open my reading list
Level D· Scientific groundwork from lab and animal studiesEvidence level of this study

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Animal Study
Journal
Int J Cardiol (2008)
Country
Netherlands
Reported sample size
15
Source database
PubMed
PMID
19046785
DOI
10.1016/j.ijcard.2008.10.024

Abstract (original English)

We investigated the effect of adipose tissue-derived stromal cells (ADSC) therapy on cardiac contractility and remodeling in the C57BL/6 mouse model of acute myocardial infarction (AMI). 30 adult male C57BL/6 mice were randomized into 2 groups, namely, AMI+media (control, n=15) and AMI+ADSC (n=15). AMI was produced by left anterior descending coronary artery ligation. After AMI induction, 1 x 10(6) ADSC or media were intramyocardially injected and the results compared. Echocardiographic and histological analyses of surviving mice (n=20) were conducted. Echocardiography was performed before cell implantation and 2 weeks after transplantation. LVEF and FS improved in the ADSC group compared to the control (P<0.01). LVEDD in the ADSC group decreased slightly from 4.65+/-0.63 mm to 4.14+/-0.53 mm compared to the control, but there was no statistical difference (P=0.072). LVESD decreased significantly in the ADSC group (P<0.05). A significant difference in scar formation and infarct size was observed between the ADSC and control group 2 weeks after AMI (P<0.05). ADSC were observed to migrate into injured sites and integrate into scar areas and increased vascular density in the infarct site compared to control group (P<0.05). Additionally, some transplanted ADSC expressed the endothelial marker. Echocardiography and histological analysis revealed that improvement in cardiac function

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.
  • • This is preclinical work; animal or laboratory results cannot be applied to humans.

Evidence level

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

How we grade evidence
Adipose Tissue, BrownAnimalsBiomarkersCell TransplantationCicatrixDisease Models, AnimalEchocardiographyHeart Function TestsImmunohistochemistryLymphokines

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research